Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of 4NQO-induced oral squamous cell carcinoma with agonistic anti-CD40 treatment

ABSTRACT: Transcriptomic analysis of 4NQO-induced oral squamous cell carcinoma with agonistic anti-CD40 treatment

PROVIDER: PRJNA898820 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic analysis of 4NQO-induced oral squamous cell carcinoma with agonistic anti-CD40 treatment

Project description:To investigate the anti-tumor effect of agonistic anti-CD40, 4NQO-indued OSCC mice with agonistic anti-CD40.

2023-10-23 | GSE217407 | GEO

Genomic analysis of 4NQO-induced mouse oral squamous cell carcinomas Genomic analysis of 4NQO-induced mouse oral squamous cell carcinomas Genomic analysis of 4NQO-induced mouse oral squamous cell carcinomas

Project description:Genomic analysis of 4NQO-induced mouse oral squamous cell carcinomas

| PRJEB32924 | ENA

Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

Project description:Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for activating the immune response to eradicate tumors. However, the translation of this approach to clinical practice has been significantly restricted due to the severe dose-limiting toxicities observed in multiple clinical trials. Here, we demonstrate that conventional type-1 dendritic cells are essential for triggering antitumor immunity but not toxicity by CD40 agonists, while macrophages, platelets, and monocytes lead to the toxic events. Therefore, we designed bispecific antibodies that target CD40 activation preferentially to dendritic cells. These bispecific reagents demonstrate a superior safety profile compared to their parental CD40 monospecific antibody, while triggering potent anti-tumor activity. We suggest such cell-selective bispecific agonistic antibodies as a drug platform to bypass the dose-limiting toxicities of anti-CD40, and of additional types of agonistic antibodies used for cancer immunotherapy.

2021-12-12 | GSE184009 | GEO

Genomic and transcriptomic landscape of a mouse model for immunotherapy in oral squamous cell carcinoma

Project description:We examined the 4-nitroquinoline-1-oxide (4NQO)-induced oral squamous cell carcinoma (OSCC) model for genetic aberrations, transcriptomic profile, and immune cell compositions at different pathological stages.

2023-08-01 | GSE229289 | GEO

Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model]

Project description:Regorafenib presented an antitumor activity in HNSCC mouse model and delayed the tumorigenesis of the 4NQO-indued oral mouse model. By tumor-infiltration lymphocytes isolation and RNA-seq analysis, the immunity-related function was activated by regorafenib. We approved that regorafenib can determine the macrophage polarization toward M1 inflammatory macrophages by suppressing the production of certain cytokines such as plasminogen activator inhibitor-1 (PAI-I) from tumor cells. Also, Regorafenib suppresses secretion of PAI-1 from ex vivo cultures of human HNSCC organoids.

2024-10-01 | GSE248154 | GEO

Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model]

2024-10-01 | GSE248153 | GEO

4NQO treatment may modulate gene expression in mouse tongue

Project description:Determine whether 4NQO treatment may modulate gene expression in mouse tongue. C57BL/6J mice were given 4NQO (100ug/ml in drink) for 8 weeks; Non-treated control samples were used for comparison.

2016-05-24 | GSE75374 | GEO

Systematic Comparison of Mouse and Human Oral Squamous Cell Carcinoma by Using Functional Transcriptomic Analysis

2015-12-17 | GSE64271 | GEO

Systematic Comparison of Mouse and Human Oral Squamous Cell Carcinoma by Using Functional Transcriptomic Analysis

Project description:This study aims to compare the global expression signature of protein coding genes between oral cancers from carcinogen-induced mice and human patients. Combinatorial treatment of 4NQO and arecoline for 8 weeks consistently induced the formation of mouse oral cancer with morphology and pathology resembling human oral squamous cell carcinoma. In this dataset, 5 mouse normal tongue and 7 tumor samples were used and Illumina Mouse Ref-8 cDNA microarray was conducted. To identify protein coding genes differentially expressed in mice oral cancers, 7 tumor tissues from carcinogen-treated mice and 5 normal tongue tissues from control mice were used in a microarray-based analysis for protein-coding gene expression patterns.

2015-12-17 | E-GEOD-64271 | biostudies-arrayexpress

Impact of anti-CD40 treatment on mouse livers

Project description:Treating samples with anti-CD40, and antibiotics to establish what transcriptional impact antibiotics is having. Anti-CD40 was found to induce a strong inflammatory signature. Antibiotics in combination with anti-CD40 attenuated this resulting in a much improved phenotype. However the detectable transcriptional differences were somewhat modest.

2021-10-25 | GSE159761 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data